Literature DB >> 6439724

A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules.

S Martino, B A Samal, A Singhakowinta, S Yoshida, M Mackenzie, J Jain, V K Vaitkevicius.   

Abstract

Thirty-six (36) women with metastatic breast cancer refractory to conventional therapies were treated with cis-diamminedichloroplatinum II. Two dose schedules were used sequentially. The first 15 patients received platinum at a dose of 15 mg/m2 daily for 5 days at 28-day intervals. No response was noted in this group. Subsequently, 21 patients were treated with a dose of 100-120 mg/m2 at 28-day intervals, but with additional induced diuresis with saline, furosemide, and mannitol. Among 13 patients evaluable for response, 2 partial responses were observed.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6439724     DOI： 10.1007/bf00390472

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  3 in total

Review 1.  New platinum complexes in clinical trials.

Authors:  F H Lee; R Canetta; B F Issell; L Lenaz
Journal:  Cancer Treat Rev       Date:  1983-03       Impact factor: 12.111

2.  Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer.

Authors:  K Kolarić; A Roth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis.

Authors:  K K Chary; D J Higby; E S Henderson; K D Swinerton
Journal:  Cancer Treat Rep       Date:  1977 May-Jun
  3 in total
  7 in total

1.  Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.

Authors:  S Martino; B A Samal; B Redman; L Flaherty; M Kraut; M Simon; M Valdivieso
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

2.  Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.

Authors:  Faruk Tas; Nese Guney; Duygu Derin; Hakan Camlica; Adnan Aydiner; Erkan Topuz
Journal:  Invest New Drugs       Date:  2007-12-29       Impact factor: 3.850

3.  Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study.

Authors:  D Amoroso; P Pronzato; G Bertelli; P Gallotti; G Pastorino; M P Cusimano; M Merlano; P F Conte; R Rosso
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

4.  Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 breast cancer cells.

Authors:  A M Otto
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 5.  Triple-negative breast cancer: role of specific chemotherapy agents.

Authors:  Steven J Isakoff
Journal:  Cancer J       Date:  2010 Jan-Feb       Impact factor: 3.360

Review 6.  Cisplatin and its analogues in the treatment of advanced breast cancer: a review.

Authors:  I E Smith; D C Talbot
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

7.  Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients.

Authors:  I E de Kruijff; A M Sieuwerts; N Beije; W J C Prager-van der Smissen; L Angus; C M Beaufort; M N Van; E Oomen-de Hoop; A Jager; P Hamberg; F E de Jongh; J Kraan; J W M Martens; S Sleijfer
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.